Epigenetic discovery and editing platform

Moonwalk Biosciences is at the forefront of developing innovative therapies through a deep understanding of epigenetics, focusing on the epigenetic code that regulates gene expression. By employing advanced profiling techniques, the company aims to return cells to their healthy states, particularly targeting cardiometabolic and obesity-related diseases. Their approach leverages a unique combination of small molecules, oligonucleotide therapeutics, and direct editing strategies, all informed by comprehensive insights into tissue specificity and gene regulation. This enables Moonwalk to identify and modulate epigenetic targets effectively, thereby advancing their internal drug discovery programs.

The company's proprietary platform, which includes the Epigenomic Foundation Model (EFM), allows for unprecedented scale in profiling and perturbation datasets. This model predicts targets that can transition cells from one state to another, facilitating the exploration of numerous combinatorial perturbations. Moonwalk's technology is distinguished by its ability to profile the epigenome at a whole-genome level with single-cell resolution, making it the first end-to-end epigenetic discovery platform of its kind. This capability not only enhances the understanding of causal relationships between the epigenome and gene expression but also supports the development of therapies that can modify pathological gene expression, ultimately leading to novel therapeutic opportunities.

United States

Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.

Moonwalk Biosciences

Company Details